Dianthus Therapeutics, Inc.
DNTHNASDAQHealthcare● Active
$81.22
+$0.71(+0.88%)
Market Cap$3.4B
P/E Ratio—
52W High$96.5
52W Low$16.64
Dianthus Therapeutics, Inc. (DNTH) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · DNTH · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $2.04M | $6.24M | $2.83M | $6.42M | $1.48M |
| Cost of Revenue | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $2.04M | $6.24M | $2.83M | $6.42M | $1.48M |
| Gross Margin %(computed) | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $145.64M | $83.11M | $32.84M | $29.38M | $12.61M |
| G&A Expenses | $34.33M | $24.99M | $18.16M | $6.74M | $1.96M |
| Total Operating Expenses | $179.97M | $108.10M | $51.00M | $36.12M | $14.56M |
| Operating Income | ($177.93M) | ($101.86M) | ($48.17M) | ($29.70M) | ($13.09M) |
| Operating Margin %(computed) | — | — | — | -462.91% | -886.59% |
| Interest Income | $16.12M | $17.36M | $4.76M | $1.15M | $0.10M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($162.34M) | ($84.97M) | ($43.55M) | ($28.48M) | ($13.11M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($162.34M) | ($84.97M) | ($43.55M) | ($28.48M) | ($13.11M) |
| Net Margin %(computed) | — | — | — | -443.76% | -888.14% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-4.20 | $-2.55 | $-8.45 | $-7.60 | $-3.82 |
| Wtd Avg Shares | 37.79M | 33.31M | 5.15M | 3.75M | 3.43M |
| EBITDA | ($177.93M) | ($101.45M) | ($47.82M) | ($29.56M) | ($13.09M) |
| EBITDA Margin %(computed) | — | — | — | -460.62% | -886.59% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Dianthus Therapeutics, Inc. data
About Dianthus Therapeutics, Inc. (DNTH) Income Statement
Dianthus Therapeutics, Inc. (DNTH) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, DNTH reported revenue of $0.00B, gross profit of $0.00B (gross margin 100.00%), and net income of ($0.16B) — a net profit margin of -7973.33%.
Frequently asked questions
DNTH · 4 questionsDianthus Therapeutics, Inc. (DNTH) reported revenue of $0.00B for 2025, down 67.3% year-over-year.
DNTH revenueDNTH salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08